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Peritoneal dialysis (PD) is associated with functional and structural changes of the peritoneal membrane. In this paper, we
describe the impact of diﬀerent factors contributing to peritoneal incompatibility of PD ﬂuid installation including presence of
a catheter, volume loading, and the PD ﬂuid components itself. These factors initiate recruitment and activation of peritoneal
immune cells such as macrophages and mast cells, as well as activation of peritoneal cells as mesothelial cells in situ. We provide
an overview of PD-associated changes as seen in our rat PD-exposure model. Since these changes are partly reversible, we
ﬁnally discuss therapeutic strategies in the rat PD model with possible consequences of long-term PD in the relevant human
setting.
1. Factors Contributing to Functional
and Structural Changes in an Experimental
RatPD Model: Introduction
Peritoneal dialysis (PD) is a therapy used to replace kidney
function in end-stage renal disease patients. The therapy is
based on the ability of the peritoneal membrane to function
as a dialysing membrane, allowing exchange of solutes and
waste products between the PD ﬂuids (PDFs) and the
circulation. Dialysis ﬂuid is instilled in the peritoneal cavity
via a permanent catheter. PDFs contain an osmotic agent,
mostly glucose, which facilitates ﬂuid movement from the
bloodstream to the peritoneal cavity leading to removal of
metabolic waste products and water. Continuous removal
of waste products achieved using PDs, results in improved
well-being of patients. In contrast, in haemodialysis, waste
products accumulate between two dialysis treatments. Fur-
thermore, patients on PD have increased mobility compared
to haemodialysis since PD can be done at home, and
m o r e o v e r ,P Di sl e s se x p e n s i v e .
However, drawbacks of PD include the risk of peritonitis
and peritoneal membrane damage upon exposure to PDF.
The latter induces inﬂammation, angiogenesis, and ﬁbrotic
changes. In this paper, we describe the usefulness of a rat PD
exposure model in deﬁning the impact of PDF components
in this process. Finally, we will discuss interventions in this
model and the possible clinical implications for long-term
PD.
2. PD-RelatedChanges as Observed in
aRat PD-ExposureModel
The eﬃcacy of PD depends on the structural and functional
integrity of the peritoneum, that is, the inner surface of
the abdominal wall (parietal peritoneum), omentum, and
mesentery (visceral peritoneum). The peritoneum consists2 International Journal of Nephrology
Table 1: The degree of contribution by extrinsic (catheter, uremia) and intrinsic (ﬂuid) factors on the peritoneum in rats.
Peritoneal changes Extrinsic factors Intrinsic factors
Catheter Uraemia (Lactate) Buﬀer Buﬀe r+G l u c o s e B u ﬀe r+G l u c o s e+G D P
Ultraﬁltration failure −± ± ++ +
Angiogenesis ±± ± ++ +
Fibrosis −− − ++ +
Mesothelial regeneration −− ++ + + +
Eﬄuent cell number −− − ++
Omental mast cells −± ++ + +
Omental milky spots −− ++ + +
GDP = glucose degradation products.
Peritoneal changes are scored from no (−), weak (±), and moderate (+) to very strong alterations (++) compared to control rats.
of a mesothelial cell (MC) monolayer and underlying con-
nective tissue interstitium comprising extracellular matrix
(ECM), blood vessels, ﬁbroblasts, and innate immune cells.
In our rat PD-exposure model, we use normal renal
function, no omentomectomy, and no addition of heparins
during PD-exposure or addition of antibiotics [1]. We have
shown that several weeks of PD results in a loss of MCs and
denuded areas in the mesothelial layer [2]. Liver imprints
of rats show increased mesothelial cell density, indicating
mesothelial regeneration [3, 4]. Among the mesothelial cells,
vimentin-positive, spindle-like-shaped cells are found indi-
cating the process of epithelial to mesenchymal transition
(EMT; [5]). Changes also take place in the submesothelial
interstitium, and ECM thickness is signiﬁcantly increased
upon PD [6–8].
Signiﬁcantly higher numbers of leukocytes are found in
the eﬄuents of PD-treated animals compared to nontreated
animals. Although the percentage of macrophages and lym-
phocytes does not change, an exchange of mast cells and
eosinophils for neutrophils is seen after PD treatment [7, 9].
Increased numbers of activated macrophages are seen in
mesentery and omentum upon PD [5], including accumu-
lations around vessel networks in the omentum, known as
milky spots [7, 10]. In a steady state, milky spots occupy a
small percentage of the total surface area of the omentum,
whereas after PDF exposure, this increases dramatically [3,
11]. Throughout the peritoneal tissues, new blood vessels
and lymphatics [7] are formed. Angiogenesis leads to a large
eﬀectivesurfaceareaexchange,contributingtoultraﬁltration
loss[12]. Furthermore, the thickened submesothelial ﬁbrotic
layer counteracts osmotic pressure further, reducing eﬃcacy
of exchange [13].
In summary, loss of mesothelium and induction of
inﬂammation and angiogenesis are typical morphologic
features seen in long-term PD which in part contribute to
ﬁbrotic changes, ultimately leading to technique failure.
In this paper, we discuss the changes that occur upon
PD in our rat PD-exposure model. This model, as described
above, shows similar changes upon long-term exposure to
PDF ﬂuid as patients on CAPD. For example, thickening
of the submesothelial compact zone, degeneration of the
MC layer, loss of microvilli on residual MC, and increased
vessel numbers are also observed in biopsies from patients
on long-term PD, as in detail described by Williams et
al. [14]. In addition, Devuyst et al. recently reviewed the
similarities between mice, rats, and humans regarding a.o.
peritoneal transport, aquaporins, and net UF afterlong-term
PD exposure [15].
3. Causesof PD-InducedPeritoneal
Membrane Changes
Several factors can contribute to PD-related changes, includ-
ing the presence of the catheter, uraemia, peritonitis, and
instillation of the volume loading of PDF itself. Moreover,
diﬀerent components of the PDF, including the used buﬀer
(low pH), glucose concentration, and glucose degradation
products (GDPs) generated during heat sterilisation, inﬂu-
ence peritoneal inﬂammation (as reviewed by Schilte et
al. [2] and summarized in Table 1). The presence of only
the catheter itself already induces PD-related morphological
changes such as increase in angiogenesis and thickness of
ECM, as well as slight eﬀect on total eﬄuent cell numbers
[9, 16]. Morphologic and inﬂammatory parameters of rats
treated with PDF via a peritoneal catheter are signiﬁcantly
increased compared to rats treated via intraperitoneal needle
injections (blood vessels, ECM thickness, and total cell
count).
Volume loading is already a second inﬂammatory trigger.
Zareie et al. showed that instillation of lactate buﬀer
without glucose or GDPs already resulted in increased cell
inﬂux, mesothelial regeneration, angiogenesis, and increased
numberofmilkyspotsalthoughitnotsigniﬁcantlyenhanced
ﬁbrosis [7, 9]. Moreover, they showed that the addition of
glucose to the buﬀer-induced angiogenesis and mesothelial
regeneration, and induced ﬁbrosis as well as cell inﬂux
even further. Finally, the presence of GDPs enhanced
all mentioned peritoneal changes, apart from cell inﬂux
and mesothelial regeneration, even further. Besides, GDPs,
advanced glycation end products (AGEs) formed by heating
of glucose, contribute to the toxicity of PDF [17].
It has become increasingly clear that more biocompatible
PDFs (bicarbonate/lactate buﬀer, reduced concentration
of glucose and GDPs) induce less damage and decrease
impaired ultraﬁltration when compared with conventional
PDF [2, 6, 8, 17].International Journal of Nephrology 3
In addition, supplementing PDF with aminoguanidine,
whichscavengesGDPsandpreventsAGEformation,resulted
inlessmesothelialdenudation[18],reducedﬁbrosis,andless
angiogenesis in omentum and parietal peritoneum, but not
in mesentery [19] as shown in our own rat PD-exposure
model.
Apart from intrinsic factors as PDF composition, other
factors have been suggested to contribute to PD-related
tissue remodelling (Table 1). Animal studies have shown the
increase in vascular network as a result of uraemia in non-
PD-treated animals. Although diﬀerences between uremic
and nonuremic rats were found in control animals (no PD),
there is no longer a prominent eﬀect of uraemia during PD
therapy [4, 20].
In contrast, peritonitis episodes always signiﬁcantly
contribute to peritoneal changes by inducing mesothelial
damage, a massive inﬂammatory response, and increased
vascularisation of peritoneal tissue leading to impaired
membrane function [12, 21, 22].
4.PeritonealRest andReversibility
Activation of peritoneal cells, mediators, and pathways,
results in functional and structural changes of peritoneal
membranes in long-term PD. Some of these changes can
be reversed by peritoneal rest. The reversibility of both
morphological and functional alterations in the peritoneal
membrane by peritoneal rest has been shown in animal
studies [23, 24].
Peritoneal rest of more than 4 weeks restored ultraﬁltra-
tion capacity as well as peritoneal permeability for glucose
and total protein [23, 24]. Moreover, the thickness of the
parietal peritoneum was reduced, and omental and mesen-
terial vessel density was restored [23, 24]. Furthermore,
peritoneal rest reversed the increased mast cell density and
milky spot response and recovered PD-induced mesothelial
damage [24]. These data suggest that PD-induced changes in
the peritoneal membrane are reversible after peritoneal rest,
atleastintheratmodel.Wethereforeforeseefuturetherapies
focusing on the prevention and reversibility of these changes
as shown below. Moreover, this may have major implications
for therapeutic clinical interventions in preventing the PD-
induced changes in long-term PD.
5. Therapeutic Interventionsin
the RatPD Model
Recent reviews of our group have shown that the rat PD
model is also ideally to test anti-inﬂammatory therapeutic
interventions [2, 25].
Heparin has been mentioned as a regulator in inﬂamma-
tion, but the addition of unfractionated or low-molecular
weight heparin was not able to counteract the PD-ﬂuid-
induced changes in our rat PD model [5], but in an editorial,
the usefulness was highlighted [26].
Recently,wecouldshowthatSunitinibinhibitsangiogen-
esis in our rat PD model, and so the usefulness of inhibitors
in the ﬁeld of angiogenesis can have important functional
implications [27]. Moreover, the usefulness of Celecoxib
as inhibitor of Cox-2 and the inﬂammation cascade has
been discussed [28] and indeed in our rat PD model, we
could demonstrate an eﬀect on angiogenesis and functional
ultraﬁltration, but not on clear inﬂammation markers [29].
These two interventions so in part show some positive
results, but future experiments should determine if no side
eﬀects of Celecoxib are seen, when used in a clinical setting
(as presently is investigated in our institute) and whether the
reduction of angiogenesis by Sunitinib really results in better
ultraﬁltration.
It must be mentioned that macrophages are thought
to play a key role in the inﬂammatory process, as earlier
discussed [2]. More recently, it was shown that the dis-
crete balance between the so-called proinﬂammatory M1
macrophages and alternatively activated M2 macrophages
might determine the outcome in inﬂammation in PD [30]
as has also been shown for macrophages in wound healing
[31] and oncology [32, 33].
Finally, molecules as bone morphogenetic protein-7
(BMP-7) and the vitamin D analogue paricalcitol have been
shown to be important in inhibiting peritoneal and renal
ﬁbrosis[34,35].BMP-7alsowasshowntopreventperitoneal
damage in our PD-exposure model [36], and preliminary
data on paricalcitol also show a clear eﬀect in our PD rat
model [37]. These observations should be investigated more
deeplyandmechanisticallyintheinvivoanimalmodel,since
theyoﬀeropportunitiesfortherapeuticclinicalinterventions
in the near future.
6. Summary and Conclusion
In long-term PD, the catheter, uraemia, peritonitis, and
permanent exposure to PDF (volume loading, glucose, and
GDP’s) result in morphological and functional changes of
the peritoneal membranes. In part, the ultraﬁltration loss
seen in PD patients is caused by the bioincompatibility of
PDF. Novel PDFs oﬀer an improvement in biocompatibility,
and further development of biocompatible ﬂuids will lead
to better preservation of the peritoneal membrane. Espe-
cially therapeutic interventions on angiogenesis, ﬁbrosis,
and inﬂammation are thought to be promising strategies
in preventing ultraﬁltration failure. We therefore foresee a
combination therapy using more biocompatible ﬂuids along
with speciﬁc inhibitors involved in peritoneal inﬂamma-
tion/angiogenesis/ﬁbrosis to be the most eﬀective approach
in future PD to prevent PD-induced changes and which will
be beneﬁcial for PD patients.
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